The emerging role of cannabinoid neuromodulators in symptom management.
Article Details
- CitationCopy to clipboard
Davis M, Maida V, Daeninck P, Pergolizzi J
The emerging role of cannabinoid neuromodulators in symptom management.
Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1.
- PubMed ID
- 17139494 [ View in PubMed]
- Abstract
INTRODUCTION: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. DISCUSSION: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. SUMMARY: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Dronabinol Cannabinoid receptor 2 Protein Humans YesAgonistDetails Nabilone Cannabinoid receptor 1 Protein Humans YesPartial agonistDetails Nabilone Cannabinoid receptor 2 Protein Humans YesPartial agonistDetails